Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1- and MSH3-associated polyposes.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
11 2019
Historique:
received: 04 03 2019
revised: 12 06 2019
accepted: 24 06 2019
pubmed: 28 6 2019
medline: 10 3 2020
entrez: 28 6 2019
Statut: ppublish

Résumé

Technological advances have allowed the identification of new adenomatous and serrated polyposis genes, and of several candidate genes that require additional supporting evidence of causality. Through an exhaustive literature review and mutational screening of 177 unrelated polyposis patients, we assessed the involvement of MCM9, FOCAD, POLQ, and RNF43 in the predisposition to (nonserrated) colonic polyposis, as well as the prevalence of NTHL1 and MSH3 mutations among genetically unexplained polyposis patients. Our results, together with previously reported data and mutation frequency in controls, indicate that: MCM9 and POLQ mutations are not associated with polyposis; germline RNF43 mutations, with a prevalence of 1.5-2.5% among serrated polyposis patients, do not cause nonserrated polyposis; MSH3 biallelic mutations are highly infrequent among European polyposis patients, and the prevalence of NTHL1 biallelic mutations among unexplained polyposes is ~2%. Although nonsignificant, FOCAD predicted deleterious variants are overrepresented in polyposis patients compared to controls, warranting larger studies to provide definite evidence in favor or against their causal association with polyposis predisposition.

Identifiants

pubmed: 31243857
doi: 10.1002/humu.23853
doi:

Substances chimiques

Biomarkers 0
FOCAD protein, human 0
MSH3 protein, human 0
MutS Homolog 3 Protein 0
Tumor Suppressor Proteins 0
RNF43 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
DNA-Directed DNA Polymerase EC 2.7.7.7
Deoxyribonuclease (Pyrimidine Dimer) EC 3.1.25.1
NTHL1 protein, human EC 3.1.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1910-1923

Subventions

Organisme : Fundación Olga Torres
Pays : International
Organisme : Instituto de Salud Carlos III
ID : CIBERONC CB16/12/00234
Pays : International
Organisme : Generalitat de Catalunya
ID : AGAUR 2017SGR1282
Pays : International
Organisme : Generalitat de Catalunya
ID : CERCA Program
Pays : International
Organisme : Generalitat de Catalunya
ID : PERIS SLT002/16/0037
Pays : International
Organisme : Generalitat de Catalunya
ID : PERIS SLT002/16/00164 (MT)
Pays : International
Organisme : Spanish Ministry of Science, Innovation and Universities, co-funded by FEDER funds-a way to build Europe
ID : SAF2015-68016-R (GC)
Pays : International
Organisme : Spanish Ministry of Science, Innovation and Universities, co-funded by FEDER funds-a way to build Europe
ID : SAF2016-80888-R (LV)
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Mariona Terradas (M)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.

Pau M Munoz-Torres (PM)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.

Sami Belhadj (S)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.

Gemma Aiza (G)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Matilde Navarro (M)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Joan Brunet (J)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain.

Gabriel Capellá (G)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Laura Valle (L)

Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH